The Swiss pharmaceutical company will acquire full rights to Sironax's proprietary brain delivery platform in an M&A deal.
Novartis has agreed to acquire full rights to Sironax's proprietary brain delivery platform, according to a market feed.
The transaction was flagged as material to Novartis, identified as a Swiss pharmaceutical company listed on the SIX exchange under the ticker NOVN.
Lucas covers M&A activity and startup funding rounds, tracking deal structures and valuations to explain what a transaction means for the companies and markets involved.
More from Lucas Ferreira →
